H2N-Nle-NHnBu | 528846-48-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: H2N-Nle-NHnBu
• 英文别名: (2S)-2-amino-N-butylhexanamide
• CAS: 528846-48-2
• 化学式: C₁₀H₂₂N₂O
• 分子量: 186.297
• InChiKey: IQWVXDGHTLVNTN-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  H2N-Nle-NHnBu 在 哌啶 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 8.0h， 生成 H2N-Cha-Nle-NHnBu
  参考文献：
  名称：

  Enantioselective Synthesis of α-Alkyl-β,γ-unsaturated Esters through Efficient Cu-Catalyzed Allylic Alkylations

  摘要：

  A method for enantioselective Cu-catalyzed allylic substitution between various alkylzincs and alpha,beta-unsaturated carboxylic esters that bear a gamma-phosphate is reported. These transformations afford alpha-alkyl-beta,gamma-unsaturated carbonyls with regioselectivities of 7:1 to >20:1 (S(N)2':S(N)2) and in 87-97% ee. The utility of the method is illustrated by a convergent total synthesis of topoisomerse II inhibitor (R)-elenic acid.

  DOI：

  10.1021/ja0300618
• 作为产物：
  描述：

  芴甲氧羰酰基正亮氨酸 在 哌啶 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 生成 H2N-Nle-NHnBu
  参考文献：
  名称：

  Enantioselective Synthesis of α-Alkyl-β,γ-unsaturated Esters through Efficient Cu-Catalyzed Allylic Alkylations

  摘要：

  A method for enantioselective Cu-catalyzed allylic substitution between various alkylzincs and alpha,beta-unsaturated carboxylic esters that bear a gamma-phosphate is reported. These transformations afford alpha-alkyl-beta,gamma-unsaturated carbonyls with regioselectivities of 7:1 to >20:1 (S(N)2':S(N)2) and in 87-97% ee. The utility of the method is illustrated by a convergent total synthesis of topoisomerse II inhibitor (R)-elenic acid.

  DOI：

  10.1021/ja0300618

文献信息

• Pyrimidine derivatives as IL-8 receptor antagonists
  申请人：——

  公开号：US20040087601A1

  公开（公告）日：2004-05-06

  Compounds containing the pyrimidine nucleus and their use to treat diseases and conditions related to inappropriate Interleukin-8 receptor activity are disclosed. The compounds are of the formula I 1 In these compounds, Q is preferably unsubstituted and substituted heterocyclyl; U is usually hydrogen or fluorine; and V is preferably hydrogen, halogen, alkyl, —O—alkyl or —S-alkyl. A representative example is: 2

  含有嘧啶核的化合物及其用于治疗与不适当的白细胞介素-8受体活性相关的疾病和症状的用途已被披露。这些化合物的结构式为I 1 在这些化合物中，Q最好是未取代或取代的杂环烷基；U通常是氢或氟；V最好是氢、卤素、烷基、—O—烷基或—S-烷基。一个代表性的例子是： 2
• Midura-Nowaczek, Krystyna; Bruzgo, Irena; Roszkowska-Jakimiec, Wieslawa, Acta poloniae pharmaceutica, 1996, vol. 53, # 3, p. 221 - 223
  作者：Midura-Nowaczek, Krystyna、Bruzgo, Irena、Roszkowska-Jakimiec, Wieslawa、Worowski, Krzysztof

  DOI：——

  日期：——
• DENDRIMERIC PEPTIDES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME
  申请人：Kallenbach Neville R.

  公开号：US20150337011A1

  公开（公告）日：2015-11-26

  Novel peptide compounds and pharmaceutical compositions thereof are disclosed that have a formula represented by the following formula (I) wherein L 1 , L 2 , L 3 , Z, R 1 , R 2 , R 4 and R 5 are as described herein. The compounds demonstrate antimicrobial activity and may be prepared as pharmaceutical compositions and used for the prevention and treatment of a variety of conditions in mammals including humans where microbial invasion is involved. The present peptides are particularly valuable as their effect is rapid, broad in spectrum and mostly indifferent to resistance provided by standard antibiotics.
• US7037916B2
  申请人：——

  公开号：US7037916B2

  公开（公告）日：2006-05-02
• [EN] PYRIMIDINE DERIVATIVES AS IL-8 RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE PYRIMIDINE UTILISES COMME ANTAGONISTES DES RECEPTEURS DE L'IL-8
  申请人：PHARMACOPEIA INC

  公开号：WO2004062609A2

  公开（公告）日：2004-07-29

  Compounds containing the pyrimidine nucleus and their use to treat diseases and conditions related to inappropriate Interleukin-8 receptor activity are disclosed. The compounds are of the formula (I). In these compounds, Q is preferably unsubstituted and substituted heterocyclyl; U is usually hydrogen or fluorine; and V is preferably hydrogen, halogen, alkyl, -O-alkyl or -S-alkyl. A representative example is formula (X).